NASDAQ:VRNA Verona Pharma (VRNA) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free VRNA Stock Alerts $16.43 -0.07 (-0.42%) (As of 10:46 AM ET) Add Compare Share Share Today's Range$16.13▼$16.7350-Day Range$15.30▼$19.0752-Week Range$11.83▼$23.81Volume45,715 shsAverage Volume511,073 shsMarket Capitalization$1.31 billionP/E RatioN/ADividend YieldN/APrice Target$33.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Verona Pharma alerts: Email Address Verona Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside100.0% Upside$33.00 Price TargetShort InterestBearish8.01% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.23Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.23) to ($0.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.79 out of 5 starsMedical Sector691st out of 939 stocksPharmaceutical Preparations Industry320th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingVerona Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.00, Verona Pharma has a forecasted upside of 100.0% from its current price of $16.50.Amount of Analyst CoverageVerona Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.01% of the outstanding shares of Verona Pharma have been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.Change versus previous monthShort interest in Verona Pharma has recently increased by 0.95%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVerona Pharma does not currently pay a dividend.Dividend GrowthVerona Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VRNA. Previous Next 4.0 News and Social Media Coverage News SentimentVerona Pharma has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Verona Pharma this week, compared to 2 articles on an average week.Search Interest9 people have searched for VRNA on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows10 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verona Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Verona Pharma is held by insiders.Percentage Held by Institutions85.88% of the stock of Verona Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verona Pharma are expected to grow in the coming year, from ($1.23) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verona Pharma is -23.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verona Pharma is -23.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerona Pharma has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> About Verona Pharma Stock (NASDAQ:VRNA)Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.Read More VRNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRNA Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comVRNA Apr 2024 17.500 callMarch 16, 2024 | finance.yahoo.comVRNA Apr 2024 15.000 callMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.March 4, 2024 | globenewswire.comAndrew Fisher Joins Verona Pharma as General CounselMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D PipelineMarch 1, 2024 | finance.yahoo.comVerona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | fool.com3 Healthcare Stocks That Have Outperformed Nvidia Since 2022February 29, 2024 | seekingalpha.comVerona Pharma plc 2023 Q4 - Results - Earnings Call PresentationMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.February 29, 2024 | finanznachrichten.deVerona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 29, 2024 | finance.yahoo.comVerona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comVerona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | markets.businessinsider.comVerona Pharma earnings preview: what to expectFebruary 25, 2024 | finance.yahoo.comWhen Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?February 25, 2024 | wsj.comVerona Pharma PLC ADRFebruary 17, 2024 | finance.yahoo.comVRNA Mar 2024 15.000 putFebruary 17, 2024 | finance.yahoo.comVRNA Jun 2024 30.000 callFebruary 15, 2024 | seekingalpha.comVerona Pharma: A Few Points From The Bull And Bear CaseFebruary 15, 2024 | finance.yahoo.comVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateFebruary 15, 2024 | globenewswire.comVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateJanuary 23, 2024 | investing.comVerona Pharma PLC ADR (VRNA)January 19, 2024 | seekingalpha.comVerona Pharma: Upcoming PDUFA, Expired Patent, Strong DataJanuary 15, 2024 | finance.yahoo.comVerona Pharma plc's (NASDAQ:VRNA) latest 11% decline adds to one-year losses, institutional investors may consider drastic measuresJanuary 11, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Verona Pharma (VRNA)January 3, 2024 | finance.yahoo.comVerona Pharma to Present at 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2024 | finanznachrichten.deVerona Pharma plc: Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules CapitalJanuary 2, 2024 | markets.businessinsider.comVerona Pharma Secures Debt Facility Of Up To $400 MlnSee More Headlines Receive VRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VRNA CUSIPN/A CIK1657312 Webwww.veronapharma.com Phone011-44-0-2032834200FaxN/AEmployees79Year FoundedN/APrice Target and Rating Average Stock Price Target$33.00 High Stock Price Target$35.00 Low Stock Price Target$32.00 Potential Upside/Downside+100.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,370,000.00 Net MarginsN/A Pretax Margin-10,946.07% Return on Equity-20.47% Return on Assets-17.72% Debt Debt-to-Equity Ratio0.20 Current Ratio33.33 Quick Ratio33.33 Sales & Book Value Annual Sales$460,000.00 Price / Sales2,867.41 Cash FlowN/A Price / Cash FlowN/A Book Value$3.12 per share Price / Book5.29Miscellaneous Outstanding Shares79,940,000Free Float76,103,000Market Cap$1.32 billion OptionableOptionable Beta0.42 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. David S. Zaccardelli Pharm.D. (Age 60)President, CEO & Executive Director Comp: $1.27MMr. Mark W. Hahn (Age 61)Chief Financial Officer Comp: $858.29kDr. Kathleen A. Rickard M.D. (Age 66)Chief Medical Officer Comp: $650.83kMr. Andrew FisherGeneral CounselMs. Victoria StewartDirector of CommunicationsMr. Matthew CasbonVP of Sales, Marketing & TrainingMs. Ostra JewellSenior Vice President of Human ResourcesDr. Tara Rheault M.P.H. (Age 47)Ph.D., Chief Development Officer Mr. Christopher MartinChief Commercial OfficerMs. Caroline DiazSenior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsCollegium PharmaceuticalNASDAQ:COLLBelite BioNASDAQ:BLTEIronwood PharmaceuticalsNASDAQ:IRWDXencorNASDAQ:XNCRPacira BioSciencesNASDAQ:PCRXView All CompetitorsInsiders & InstitutionsWellington Management Group LLPSold 683,577 shares on 3/5/2024Ownership: 4.734%Goldman Sachs Group Inc.Bought 14,668 shares on 3/1/2024Ownership: 0.050%Perceptive Advisors LLCSold 140,983 shares on 2/26/2024Ownership: 4.836%Eventide Asset Management LLCBought 527,781 shares on 2/20/2024Ownership: 1.724%Citadel Advisors LLCBought 100 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions VRNA Stock Analysis - Frequently Asked Questions Should I buy or sell Verona Pharma stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRNA shares. View VRNA analyst ratings or view top-rated stocks. What is Verona Pharma's stock price target for 2024? 3 brokerages have issued 12-month price targets for Verona Pharma's shares. Their VRNA share price targets range from $32.00 to $35.00. On average, they expect the company's share price to reach $33.00 in the next year. This suggests a possible upside of 100.0% from the stock's current price. View analysts price targets for VRNA or view top-rated stocks among Wall Street analysts. How have VRNA shares performed in 2024? Verona Pharma's stock was trading at $19.88 at the start of the year. Since then, VRNA shares have decreased by 17.0% and is now trading at $16.50. View the best growth stocks for 2024 here. When is Verona Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VRNA earnings forecast. How were Verona Pharma's earnings last quarter? Verona Pharma plc (NASDAQ:VRNA) released its quarterly earnings data on Thursday, February, 29th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.07. What ETF holds Verona Pharma's stock? ALPS Medical Breakthroughs ETF holds 60,171 shares of VRNA stock, representing 1.19% of its portfolio. What other stocks do shareholders of Verona Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT). When did Verona Pharma IPO? Verona Pharma (VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. Who are Verona Pharma's major shareholders? Verona Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (4.84%), Wellington Management Group LLP (4.73%), Jennison Associates LLC (1.98%), Eventide Asset Management LLC (1.72%), First Turn Management LLC (1.51%) and Bellevue Group AG (1.05%). Insiders that own company stock include Anders Ullman, Claire Poll, David R Ebsworth, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Martin Edwards, Orbimed Advisors Llc and Patrick John Finn. View institutional ownership trends. How do I buy shares of Verona Pharma? Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRNA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.